← Back to Search
Nab-paclitaxel In The Treatment Of Metastatic Breast Cancer: A Comprehensive Review
A. Montero, B. Adams, C. Diaz-Montero, Stefan Glück
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane®) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol®) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.
This paper references
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
S. Jones (2005)
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Joanne L. Blum (2007)
Gemcitabine and taxanes in metastatic breast cancer: a systematic review
Vinay Gudena (2008)
Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies
T. Stinchcombe (2008)
N. Dubrawsky (1989)
Cancer Statistics, 2009
A. Jemal (2009)
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
D. Nyman (2005)
International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
F. Cardoso (2009)
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
A. Moreno-Aspitia (2005)
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
V. Roy (2009)
Los Angeles, CA, USA
J. Cohen (2002)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
N. Desai (2006)
[A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
Xiao-yu Teng (2004)
Albuminbound paclitaxel: in metastatic breast cancer
DM Robinson (2006)
A systematic review of taxane-containing regimens for metastatic breast cancer
D. Ghersi (2005)
Bristol-Myers Squibb Company
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
M. Piccart-Gebhart (2008)
D. Robinson (2012)
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.
I. Ringel (1991)
Abraxane) in combination with gemcitabine in patients with metastatic breast cancer
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
N. Ibrahim (2002)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
W. Gradishar (2009)
Measurement of fraction unbound paclitaxel in human plasma.
E. Brouwer (2000)
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.
C. Lobo (2007)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
A. Seidman (2008)
Albumin-bound nanoparticle paclitaxel.
W. Gradishar (2005)
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
C. Lobo (2010)
Chemotherapy for metastatic breast cancer.
S. Barni (2005)
Weekly paclitaxel in the adjuvant treatment of breast cancer.
J. Sparano (2008)
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
K. Albain (2008)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
N. Ibrahim (2005)
This paper is referenced by
Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice
S. Valetti (2013)
Breast Cancer Receptors and Targeting Strategies
Ashish Pandit (2019)
Albendazole loaded albumin nanoparticles for ovarian cancer therapy
Lubna Noorani (2014)
Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
Dennis J. Robins (2017)
Maßgeschneiderte Nanopartikel für den Wirkstofftransport in der Krebstherapie
Tianmeng Sun (2014)
Analysis of Biotinylated Generation 4 Poly(amidoamine) (PAMAM) Dendrimer Distribution in the Rat Brain and Toxicity in a Cellular Model of the Blood-Brain Barrier
R. Hemmer (2013)
Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy.
V. Chaturvedi (2018)
Controlled drug delivery vehicles for cancer treatment and their performance
S. Senapati (2018)
Decrease of Let-7f in Low-Dose Metronomic Paclitaxel Chemotherapy Contributed to Upregulation of Thrombospondin-1 in Breast Cancer
Weiyang Tao (2015)
In vitro and in vivo evaluation of effect of excipients in local delivery of paclitaxel using microporous infusion balloon catheters.
Jordan A. Anderson (2017)
SEOM clinical guidelines for the management of metastatic breast cancer 2013.
A. Cussac (2013)
The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis
Caihua Liang (2015)
Eribulin monotherapy in a patient with heavily pretreated metastatic breast cancer: Case study and review of the literature
Fariborz Gorouhi (2012)
Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy
Ewelina Piktel (2016)
Disulfide-crosslinked reduction-responsive Prodrug Micelles for On-demand Paclitaxel Release
Zhonghang Wang (2019)
Recent advances in multifunctional silica-based hybrid nanocarriers for bioimaging and cancer therapy.
Wei Qi Lim (2016)
Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.
Faquan Li (2018)
Development of nanotheranostics against metastatic breast cancer--A focus on the biology & mechanistic approaches.
A. Subramanian (2015)
Development and application of flow experiments for quantitative studies on nanoparticle binding to biological surfaces
Ellen Broda (2016)
Self-assembled serum albumin–poly(L-lactic acid) nanoparticles: a novel nanoparticle platform for drug delivery in cancer
Lin Dai (2015)
Inorganic Compounds Going NANO
Alexandra R. Fernandess (2015)
In contrast to solvent-based taxane regimens, nab-paclitaxel does not require steroid premedication, and may be an option for patients who exhibit hypersensitivity to solvent-based taxane preparations. Practice Points Taxane chemotherapy treatment for metastatic breast cancer MANAGEMENT PERSPECTIVE
Della F. Makower (2013)
Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
R. Gowda (2014)
The mesenchymal tumor microenvironment
E. Cukierman (2012)
Multi-stimuli-responsive biohybrid nanoparticles with cross-linked albumin coronae self-assembled by a polymer-protein biodynamer.
L. Wang (2017)
Annals of Medicinal Chemistry and Research
Carolina Mota (2015)
Melissa officinalis L. ethanolic extract inhibits the growth of a lung cancer cell line by interfering with the cell cycle and inducing apoptosis.
D. B. Magalhães (2018)
Nanocrystals for the parenteral delivery of poorly water-soluble drugs.
B. Sun (2012)
An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
Xinzhe Yu (2015)
Novel Cytotoxic Agents in the Treatment of Metastatic Breast Cancer
Sean Warsch (2012)
Hybrid protein-synthetic polymer nanoparticles for drug delivery.
N. Koseva (2015)
Enhanced Targeted Delivery of Cyclodextrin-Based Supermolecules by Core-Shell Nanocapsules for Magnetothermal Chemotherapy.
I. Lin (2016)See more